These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 1318805)

  • 1. Evidence for transfer of cellular and humoral immunity to cytomegalovirus from donor to recipient in allogeneic bone marrow transplantation.
    Boland GJ; Vlieger AM; Ververs C; De Gast GC
    Clin Exp Immunol; 1992 Jun; 88(3):506-11. PubMed ID: 1318805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.
    Walter EA; Greenberg PD; Gilbert MJ; Finch RJ; Watanabe KS; Thomas ED; Riddell SR
    N Engl J Med; 1995 Oct; 333(16):1038-44. PubMed ID: 7675046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulins A, G, and M to cytomegalovirus during recurrent infection in recipients of allogeneic bone marrow transplantation.
    Engelhard D; Weinberg M; Or R; Shaked O; Naparstek E; Haikin H; Slavin S; Sarov I
    J Infect Dis; 1991 Mar; 163(3):628-30. PubMed ID: 1847402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus immunity in allogeneic marrow grafting.
    Gratama JW; Middeldorp JM; Sinnige LG; van der Meer JW; D'Amaro J; Jansen J; Zwaan FE; Brand A; de Gast GC; The TH
    Transplantation; 1985 Nov; 40(5):510-4. PubMed ID: 2997951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salivary immunoglobulins in recipients of bone marrow grafts. III. A longitudinal follow-up of CMV specific antibodies.
    Chaushu G; Chaushu S; Slavin S; Or R; Garfunkel AA; Yefenof E
    Bone Marrow Transplant; 1996 Feb; 17(2):237-41. PubMed ID: 8640173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus antibody avidity in allogeneic bone marrow recipients: evidence for primary or secondary humoral responses depending on donor immune status.
    Lutz E; Ward KN; Szydlo R; Goldman JM
    J Med Virol; 1996 May; 49(1):61-5. PubMed ID: 8732861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease.
    Reusser P; Riddell SR; Meyers JD; Greenberg PD
    Blood; 1991 Sep; 78(5):1373-80. PubMed ID: 1652311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different kinetics in anti-cytomegalovirus immunity reconstitution evaluated by lymphocyte proliferation and IFN-gamma production in allogeneic and autologous bone marrow transplantation.
    Mendes AV; Benard G; Pereira CB; Kallas EG; Duarte AJ; Pannuti CS; Dulley FL; Machado CM
    Acta Haematol; 2002; 107(4):187-94. PubMed ID: 12053145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus prophylaxis and treatment following bone marrow transplantation.
    Tsinontides AC; Bechtel TP
    Ann Pharmacother; 1996 Nov; 30(11):1277-90. PubMed ID: 8913411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunity related to cytomegalovirus after allogenic bone marrow transplantation: role of donor immunity to cytomegalovirus in the incidence of cytomegalovirus infection in recipients].
    Rabian-Herzog C; Varrin F; Gluckmann E; Bertrand C; Harzic M; Ferchal F
    Rev Fr Transfus Immunohematol; 1984 Jun; 27(3):331-6. PubMed ID: 6091224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis.
    Li CR; Greenberg PD; Gilbert MJ; Goodrich JM; Riddell SR
    Blood; 1994 Apr; 83(7):1971-9. PubMed ID: 8142663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CMV-Specific Immune Response-New Patients, New Insight: Central Role of Specific IgG during Infancy and Long-Lasting Immune Deficiency after Allogenic Stem Cell Transplantation.
    Zdziarski P
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30641912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct genotypic distributions of cytomegalovirus (CMV) envelope glycoprotein in bone marrow and renal transplant recipients with CMV disease.
    Woo PC; Lo CY; Lo SK; Siau H; Peiris JS; Wong SS; Luk WK; Chan TM; Lim WW; Yuen KY
    Clin Diagn Lab Immunol; 1997 Sep; 4(5):515-8. PubMed ID: 9302197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus infection in recipients of related and unrelated donor bone marrow transplants: no evidence of increased incidence in patients receiving unrelated donor grafts.
    Foot AB; Pamphilon D; Caul EO; Roome AP; Hunt LP; Cornish JM; Oakhill A
    Br J Haematol; 1998 Aug; 102(3):671-7. PubMed ID: 9722292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro.
    Greenberg PD; Reusser P; Goodrich JM; Riddell SR
    Ann N Y Acad Sci; 1991 Dec; 636():184-95. PubMed ID: 1665321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgG-subclass-specific CMV reactivity in bone marrow transplant recipients.
    Wahren B; Linde A; Sundqvist VA; Ljungman P; Lönnqvist B; Ringdén O
    Transplantation; 1984 Nov; 38(5):479-83. PubMed ID: 6093297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.
    Zaia JA; Schmidt GM; Chao NJ; Rizk NW; Nademanee AP; Niland JC; Horak DA; Lee J; Gallez-Hawkins G; Kusnierz-Glaz CR
    Biol Blood Marrow Transplant; 1995 Dec; 1(2):88-93. PubMed ID: 9118297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation.
    Zekri AR; Mohamed WS; Samra MA; Sherif GM; El-Shehaby AM; El-Sayed MH
    Transpl Immunol; 2004 Dec; 13(4):305-11. PubMed ID: 15589744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections.
    Grob JP; Grundy JE; Prentice HG; Griffiths PD; Hoffbrand AV; Hughes MD; Tate T; Wimperis JZ; Brenner MK
    Lancet; 1987 Apr; 1(8536):774-6. PubMed ID: 2882184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.